naltrexone and bupropion

naltrexone has been researched along with bupropion in 151 studies

Research

Studies (151)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.66)	18.2507
2000's	23 (15.23)	29.6817
2010's	96 (63.58)	24.3611
2020's	31 (20.53)	2.80

Authors

Authors	Studies
Carroll, FI	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Dalvie, D; Loi, CM; Smith, DA	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Allen, JP; Litten, RZ	1
Golding, M; Hatsukami, DK; Jamerson, BD; Kotlyar, M	1
Folk, JE; Isgor, C; Rice, KC; Torregrossa, MM; Watson, SJ; Woods, JH	1
Jepson, C; Lerman, C; Lynch, KG; Patterson, F; Perkins, K; Rukstalis, M; Strasser, A	1
Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E	1
O'Brien, CP	1
Dannon, PN; Gonopolski, Y; Kotler, M; Lowengrub, K; Musin, E	1
Beilby, JJ; Doran, CM; Duszynski, KM; Mattick, RP	1
Crooks, PA; Hamad, MO; Kiptoo, PK; Stinchcomb, AL	2
Jasmin, L; Narasaiah, M; Tien, D	1
Leary, V; Meandzija, B; O'Malley, SS; Salovey, P; Toll, BA; Wu, R	1
Dannon, PN; Gonopolsky, Y; Kotler, M; Lowengrub, K; Musin, E	1
Crooks, PA; Hamad, MO; Hammell, DC; Kiptoo, PK; Paudel, KS; Stinchcomb, AL	1
Tyndale, R	1
McKee, SA	1
Anderson, JW; Atkinson, RL; Cowley, MA; Dunayevich, E; Fujioka, K; Gadde, KM; Greenway, FL; Gupta, AK; Guttadauria, M; O'Neil, P; Schumacher, D; Smith, D; Tollefson, GD; Weber, E; Whitehouse, MJ	1
Chau, DL; Nguyen, L; Nguyen, Q; Plodkowski, RA; St Jeor, S; Sundaram, U	1
Fujioka, K; Lee, MW	1
Burnand, B; Nanchen, D; Peytremann-Bridevaux, I; Walther, MR; Willi, C	1
Padwal, R	1
Cowley, MA; Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Tollefson, G	1
Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS	1
Kaplan, LM	1
Dunayevich, E; Erickson, JS; Foreyt, JP; Foster, GD; Hill, JO; Kim, DD; Klein, S; Maier, HN; O'Neil, PM; Perri, MG; Pi-Sunyer, FX; Rock, CL; Wadden, TA	1
Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA	1
Astrup, A	1
Citrome, L	2
Hatzitolios, AI; Katsiki, N; Mikhailidis, DP	1
Billes, SK; Greenway, FL	1
Faria, AM; Halpern, A; Halpern, B	1
Bray, GA; Ryan, DH	1
Gwinn, KM; Hurren, KM; Makowski, CT	1
Bodnik, D; Dannon, P; Kotler, M; Rosenberg, O; Shoenfeld, N	1
Goldfine, AB; Hiatt, WR; Thomas, A	1
Gosden, J; Heal, DJ; Smith, SL	1
Mercer, SL	1
Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J	1
Athanacio, J; Clapper, JR; D'Souza, L; Griffin, PS; Parkes, DG; Roth, JD; Wittmer, C	1
Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H	1
Rodgers, RJ; Wright, FL	1
Billes, SK; Burns, C; Dunayevich, E; Fujioka, K; Greenway, FL; Gupta, AK; Kim, D; Smith, SR	1
Howland, RH	2
Brensilver, M; Heinzerling, KG; Shoptaw, S	1
Caparelli, EC; Dunayevich, E; Telang, F; Tomasi, D; Volkow, ND; Wang, GJ; Wang, R	1
Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R	1
Billes, SK; Cowley, MA; Sinnayah, P	1
Bello, NT; Verpeut, JL	1
Nakazato, M; Ueno, H	1
Aldhoon-Hainerová, I; Hainer, V	1
Hainer, V	1
Aronne, LJ	1
Cunningham, JW; Wiviott, SD	1
Fisher, DC; Fletcher, PJ; Guy, EG; Higgins, GA	1
Albert, L; Caixàs, A; Capel, I; Rigla, M	1
Goutier, W; Kloeze, M; McCreary, AC	1
Rubio, MA	1
Glaser, PE; Hays, LR; Pike, E; Rush, CR; Stoops, WW	1
Hawkes, N	1
Buehler, AM	1
Mehr, SR; Zimmerman, MP	1
Dahiya, N; Kakkar, AK	1
Fujioka, K	1
Nau, JY	1
Greig, SL; Keating, GM	1
Bragg, R; Crannage, E	1
Chen, S; Gilder, K; Greenway, FL; Klassen, P; Kolotkin, RL	1
Ali, KF; Aronne, LJ; Shukla, AP	1
Apovian, CM	1
Megyeri, J; Nuffer, W; Trujillo, JM	1
Psaty, BM; Sharfstein, JM	1
Bakris, G; Buse, JB; Nissen, SE; Perez, A; Prcela, L; Smith, SR; Wadden, T; Wolski, KE	1
Lewis, RJ; Tolles, J	1
Wise, J	1
Malik, S; Ogden, S; Puri, MR; Sahl, R	1
Allen, S; Grabowski, J; Hatsukami, DK; Mooney, ME; Oliver, A; Pentel, P; Schmitz, JM	1
Klein, JW	1
Alfaris, N; Kyle, TK; Nadai, J; Stanford, FC	1
Fujioka, K; Gilder, K; Greenway, FL; O'Neil, PM; Plodkowski, R; Walsh, B	1
Dybala, C; Foreyt, JP; Halseth, AE; Herrmann, K; Hong, K; Lam, H	1
Braverman-Panza, J; Fujioka, K	1
Halpern, B; Mancini, MC	1
Hor, A; Purtell, L	1
Brown, WA; Man Lee, CC; Oldfield, BJ; Stefanidis, A	1
Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B	1
Cassel, KP; Eckersley, D; Moscati, RM; Singh, PA	1
Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH	1
Curry, SA	1
Blundell, JE; Dalton, M; Duarte, C; Finlayson, G; Halseth, AE; Walsh, B	1
Wilding, JPH	2
Goldberg, A; Kim, S; Ninh, A	1
Dunayevich, E; Guerdjikova, AI; Halseth, AE; McElroy, SL; Shan, K; Walsh, B	1
Abdel-Gawad, SA; Hassan, SA	1
Dilley, JE; Froehlich, JC; Nicholson, ER	1
Bersoux, S; Byun, TH; Chaliki, SS; Poole, KG	1
Daniels, S; Flynn, A; Horman, T; Hudson, R; Leri, F; Levy, A; Zhou, Y	1
Caparelli, EC; Kojori, ES; Tomasi, D; Volkow, ND; Wang, GJ; Wang, R; Wiers, CE; Zhao, J	1
Achenbach, C; Akanbi, MO; Bilaver, LA; Carroll, AJ; Hitsman, B; Jordan, N; McHugh, MC; Murphy, R; O'Dwyer, LC	1
Barrea, L; Cataldi, M; Colao, A; Guida, B; Muscogiuri, G; Savastano, S; Taglialatela, M	1
Acevedo, LM; Apovian, CM; Dunayevich, E; Greenway, FL; McElroy, SL; Pi-Sunyer, X	1
Garbutt, JC; Kampov-Polevoy, AB; Luhn, KL; Navarro, M; Thiele, TE	1
Bello, NT	1
Chatzis, P; Dinas, K; Makris, V; Pratilas, GC; Sotiriadis, A; Tziomalos, K	1
Garbutt, JC; Kampov-Polevoy, A; Navarro, M; Pedersen, C; Thiele, TE; Walter, TJ	1
Aronson, JK; Heneghan, CJ; Lee, JJ; Mahtani, KR; Onakpoya, IJ	1
Aloi, M; Arturi, F; Calabrò, G; Carbone, EA; Caroleo, M; Condoleo, F; de Filippis, R; Rania, M; Segura-Garcia, C; Staltari, FA	1
Capasso, A; De Biasio, V; Di Munzio, W; Foggia, G; Milano, W	1
Kenny, PJ; O'Brien, CP; Pierce, RC; Swinford-Jackson, SE; Unterwald, EM; Vanderschuren, LJMJ	1
Barrea, L; Colao, A; Laudisio, D; Muscogiuri, G; Pugliese, G; Savastano, S	1
Brown, SA; Izzy, M; Watt, KD	1
Grilo, CM; Gueorguieva, R; Lydecker, JA; Morgan, PT	1
Chung, WK; Febres, G; Holleran, S; Korner, J; LeDuc, CA; Mullally, JA; Ramakrishnan, R; Reid, TJ	1
Bajaj, HS; Barakat, M; Blavignac, J; Burrows, M; Camacho, F; Gould, E; Paron, E	1
Lee, SY; Tak, YJ	1
Berghold, A; Horvath, K; Jeitler, K; Krenn, C; Semlitsch, T; Siebenhofer, A; Winterholer, S	1
Bart, G; Carmody, T; Coffin, P; Dela Cruz, A; Ghitza, UE; Kim, M; Ling, W; Nunes, EV; Rush, AJ; Schmitz, J; Sharma, G; Shoptaw, S; Shores-Wilson, K; Sonne, SC; Sparenborg, S; Trivedi, MH; Wahle, A; Wakhlu, S; Walker, R; Wiest, K	1
Abawi, O; van den Akker, ELT; van der Valk, ES; van der Voorn, B; van Rossum, EFC; Welling, MS	1
Aguilar-Salinas, C; Benchimol, A; Bonilha, I; Carvalho, LSF; Cercato, C; Geloneze, B; Hohl, A; Luchiari, B; Moura, F; Nadruz, W; Sposito, AC	1
Alves, M; Areal, J; Caldas, R; Campos-Lopes, S; Guimarães, MJ; Pereira, T	1
Barakat, M; Blavignac, J; Burrows, M; Camacho, F; Christensen, RAG; Gould, E; Kamran, E; Wharton, S; Yin, P	1
Barbosa, MP; Carneiro, MG; Costa, JA; de Freitas, MFL; de Souza, IA; de Vasconcelos, DAA; do Nascimento, E; Dos Santos Oliveira, L; Lopes de Souza, S; Matos, RJB; Roberto da Silva, G	1
Correa, OMT; Doretto-Silva, L; Morreale, S; Nassis, C; Petri, G; Santos, JFRD; Scudeler, MA; Veridiano, JM	1
Bierut, LJ; Grucza, RA; Mintz, CM; Presnall, N; Xu, KY	1
Adnan, JA; El Hayek, SA; Geagea, LE; Kobeissy, F; Shatila, MA; Talih, FR	1
Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO	1
Alcorn, JL; Bolin, BL; Hays, LR; Lile, JA; Rayapati, AO; Regnier, SD; Reynolds, AR; Rush, CR; Stoops, WW	1
Hill, A; Levi, J; Venter, F; Wang, J	1
Carmody, T; Northrup, TF; Schmitz, JM; Shoptaw, S; Stotts, AL; Trivedi, MH; Villarreal, YR; Weaver, MF; Yammine, L; Yoon, JH	1
Carmody, T; Cook, RR; Korthuis, PT; Levander, XA; Potter, JS; Shoptaw, S; Trivedi, MH	1
BouSaba, J; Camilleri, M; Dilmaghani, S; Prokop, LJ; Vosoughi, K	1
Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K	1
Carmody, TJ; Coffin, PO; Kidd, JD; Levin, FR; Nunes, EV; Shoptaw, SJ; Smiley, SL; Trivedi, MH	1
Lindblad, AJ; Luu, T; Paige, A; Thomas, B	2

Reviews

53 review(s) available for naltrexone and bupropion

Article	Year
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy. Journal of medicinal chemistry, 2003, May-08, Volume: 46, Issue:10 Topics: Animals; Biogenic Monoamines; Biological Transport; Carrier Proteins; Cocaine; Fluorescent Dyes; Humans; Isoquinolines; Ligands; Morphinans; Narcotic Antagonists; Piperidines; Protein Binding; Radioisotopes; Receptors, Opioid; Structure-Activity Relationship; Substance-Related Disorders	2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings. Journal of substance abuse treatment, 1999, Volume: 16, Issue:2 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Bupropion; Forecasting; Humans; Methadyl Acetate; Naltrexone; Substance-Related Disorders; Taurine; Tobacco Use Disorder	1999
Effect of nonnicotine pharmacotherapy on smoking behavior. Pharmacotherapy, 2001, Volume: 21, Issue:12 Topics: Amphetamines; Bupropion; Clonidine; Doxepin; Humans; Naltrexone; Nortriptyline; Selective Serotonin Reuptake Inhibitors; Smoking Cessation	2001
Pharmacological treatments of pathological gambling. Journal of gambling studies, 2005,Spring, Volume: 21, Issue:1 Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Fluvoxamine; Gambling; Humans; Naltrexone; Outcome Assessment, Health Care; Paroxetine; Piperazines; Research Design; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Triazoles	2005
Anticraving medications for relapse prevention: a possible new class of psychoactive medications. The American journal of psychiatry, 2005, Volume: 162, Issue:8 Topics: Alcoholism; Behavior, Addictive; Bupropion; Cocaine-Related Disorders; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Psychotropic Drugs; Secondary Prevention; Substance-Related Disorders; Tobacco Use Disorder	2005
Developing human laboratory models of smoking lapse behavior for medication screening. Addiction biology, 2009, Volume: 14, Issue:1 Topics: Alcohol Drinking; Arousal; Bupropion; Cues; Drug Evaluation, Preclinical; Humans; Models, Psychological; Motivation; Naltrexone; Nicotine; Psychotropic Drugs; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Social Facilitation; Tobacco Use Disorder	2009
Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:6 Topics: Animals; Bupropion; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Naltrexone; Obesity; Weight Loss	2009
Naltrexone for the treatment of obesity: review and update. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:11 Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Feeding Behavior; Humans; Naltrexone; Narcotic Antagonists; Obesity; Opioid Peptides; Weight Loss	2009
Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:10 Topics: Administration, Oral; Animals; Appetite; Bupropion; Controlled Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Drug Combinations; Energy Metabolism; Humans; Naltrexone; Narcotic Antagonists; Obesity; Weight Loss	2009
Pharmacologic therapies for obesity. Gastroenterology clinics of North America, 2010, Volume: 39, Issue:1 Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; Ephedrine; Fenfluramine; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Weight Gain; Weight Loss	2010
Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR. Drugs in R&D, 2010, Volume: 10, Issue:1 Topics: Animals; Anti-Obesity Agents; Bupropion; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Drug Combinations; Drug Evaluation, Preclinical; Drugs, Investigational; Humans; Naltrexone; Obesity	2010
Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? Annals of medicine, 2011, Volume: 43, Issue:4 Topics: Bupropion; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Naltrexone; Obesity; Weight Loss	2011
Combination therapy with naltrexone and bupropion for obesity. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:11 Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Humans; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Weight Loss	2011
Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obesity facts, 2011, Volume: 4, Issue:6 Topics: Anti-Obesity Agents; Bupropion; Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Naltrexone; Obesity; Quality of Life; Waist Circumference; Weight Loss	2011
A review of late-stage CNS drug candidates for the treatment of obesity. International journal of obesity (2005), 2013, Volume: 37, Issue:1 Topics: Anti-Obesity Agents; Bupropion; Central Nervous System Stimulants; Drug Administration Schedule; Drug Approval; Drug Combinations; Drug Design; Drugs, Investigational; Female; Guidelines as Topic; Humans; Male; Naltrexone; Obesity; Patient Selection; Phentermine; Receptor, Serotonin, 5-HT2C; Risk Factors; Risk Reduction Behavior; United Kingdom	2013
ACS chemical neuroscience molecule spotlight on contrave. ACS chemical neuroscience, 2011, Sep-21, Volume: 2, Issue:9 Topics: Anti-Obesity Agents; Bupropion; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Approval; Drug Combinations; Humans; Naltrexone; Obesity; Overweight; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Weight Loss	2011
Recent advancements in drug treatment of obesity. Clinical medicine (London, England), 2012, Volume: 12, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss	2012
Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug and alcohol review, 2013, Volume: 32, Issue:5 Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Bupropion; Central Nervous System Stimulants; Humans; Methylphenidate; Naltrexone; Randomized Controlled Trials as Topic	2013
Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacological research, 2014, Volume: 84 Topics: Antidepressive Agents, Second-Generation; Bupropion; Drug Therapy, Combination; Energy Metabolism; Humans; Naltrexone; Narcotic Antagonists; Obesity; Weight Loss	2014
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert opinion on drug safety, 2014, Volume: 13, Issue:6 Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Naltrexone; Obesity; Weight Loss	2014
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3 Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate	2014
Tolerability and safety of the new anti-obesity medications. Drug safety, 2014, Volume: 37, Issue:9 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate	2014
Overview of new antiobesity drugs. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2014
Evolving directions in obesity management. The Journal of family practice, 2014, Volume: 63, Issue:7 Suppl Topics: Anti-Obesity Agents; Bupropion; Dopamine Uptake Inhibitors; Forecasting; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Liraglutide; Naltrexone; Narcotic Antagonists; Obesity; Receptors, Glucagon	2014
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. Clinical cardiology, 2014, Volume: 37, Issue:11 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Fructose; Heart; Humans; Naltrexone; Obesity; Phentermine; Topiramate	2014
Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug design, development and therapy, 2014, Volume: 8 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Naltrexone; Obesity	2014
Drug treatment of obesity: current status and future prospects. European journal of internal medicine, 2015, Volume: 26, Issue:2 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Drug Combinations; Drug Therapy, Combination; Fructose; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate	2015
Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring, Md.), 2015, Volume: 23 Suppl 1 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss	2015
Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. Journal of psychosocial nursing and mental health services, 2015, Volume: 53, Issue:6 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Liraglutide; Melatonin; Naltrexone; Obesity; Psychotropic Drugs; Weight Gain	2015
Naltrexone ER/Bupropion ER: A Review in Obesity Management. Drugs, 2015, Volume: 75, Issue:11 Topics: Adult; Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Naltrexone; Obesity; Overweight	2015
Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity. Expert review of clinical pharmacology, 2016, Volume: 9, Issue:1 Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Approval; Drug Combinations; Humans; Naltrexone; Obesity	2016
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. Future cardiology, 2016, Volume: 12, Issue:2 Topics: Adult; Anti-Obesity Agents; Bupropion; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Naltrexone; Obesity; Weight Loss	2016
A Comparison of New Pharmacological Agents for the Treatment of Obesity. The Annals of pharmacotherapy, 2016, Volume: 50, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2016
Prader-Willi Syndrome, Management of Impulsivity, and Hyperphagia in an Adolescent. Journal of child and adolescent psychopharmacology, 2016, Volume: 26, Issue:4 Topics: Adolescent; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Hyperphagia; Impulsive Behavior; Naltrexone; Prader-Willi Syndrome	2016
Pharmacotherapy for Substance Use Disorders. The Medical clinics of North America, 2016, Volume: 100, Issue:4 Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline	2016
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Expert opinion on drug safety, 2017, Volume: 16, Issue:1 Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate	2017
Practical Use of Pharmacotherapy for Obesity. Gastroenterology, 2017, Volume: 152, Issue:7 Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain	2017
Medication use for the treatment of diabetes in obese individuals. Diabetologia, 2018, Volume: 61, Issue:2 Topics: Animals; Benzazepines; Bupropion; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Lactones; Naltrexone; Obesity; Orlistat	2018
Naltrexone/bupropion for obesity. Drug and therapeutics bulletin, 2017, Volume: 55, Issue:11 Topics: Anti-Obesity Agents; Bupropion; Chemotherapy, Adjuvant; Drug Combinations; Humans; Naltrexone; Obesity, Morbid; Randomized Controlled Trials as Topic	2017
Pharmacotherapy for obesity: What you need to know. Cleveland Clinic journal of medicine, 2017, Volume: 84, Issue:12 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine	2017
The efficacy of smoking cessation interventions in low- and middle-income countries: a systematic review and meta-analysis. Addiction (Abingdon, England), 2019, Volume: 114, Issue:4 Topics: Adult; Behavior Therapy; Bupropion; Cigarette Smoking; Clonidine; Counseling; Developing Countries; Humans; Mobile Applications; Naltrexone; Nortriptyline; Randomized Controlled Trials as Topic; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Cessation Devices; Varenicline	2019
Gender-related issues in the pharmacology of new anti-obesity drugs. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2019, Volume: 20, Issue:3 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Liraglutide; Male; Naltrexone; Obesity; Patient Selection; Sex Factors; Topiramate; Treatment Outcome; Weight Loss	2019
The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. Folia medica, 2018, Dec-01, Volume: 60, Issue:4 Topics: Androgens; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Insulin Resistance; Liraglutide; Naltrexone; Obesity; Orlistat; Polycystic Ovary Syndrome; Weight Loss	2018
Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. British journal of clinical pharmacology, 2020, Volume: 86, Issue:4 Topics: Bupropion; Drug Combinations; Humans; Naltrexone; Obesity	2020
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. Endocrine, metabolic & immune disorders drug targets, 2020, Volume: 20, Issue:8 Topics: Anti-Obesity Agents; Bupropion; Epidemics; Global Health; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Precision Medicine; Weight Loss	2020
New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. Minerva endocrinologica, 2020, Volume: 45, Issue:2 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Endocrinology; Humans; Liraglutide; Naltrexone; Nutritional Sciences; Obesity	2020
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential. Hepatology (Baltimore, Md.), 2021, Volume: 73, Issue:5 Topics: Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Humans; Liraglutide; Liver Cirrhosis; Liver Transplantation; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Translational Science, Biomedical	2021
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Current obesity reports, 2021, Volume: 10, Issue:1 Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss	2021
Long-term effects of weight-reducing drugs in people with hypertension. The Cochrane database of systematic reviews, 2021, 01-17, Volume: 1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Bias; Blood Pressure; Body Weight; Bupropion; Diet, Reducing; Drug Combinations; Female; Fructose; Humans; Hypertension; Lactones; Male; Middle Aged; Naltrexone; Orlistat; Phentermine; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Time; Topiramate	2021
Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2021, Volume: 22, Issue:6 Topics: Bupropion; Child; Female; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Smoking Cessation; Tobacco Use Cessation Devices; Weight Loss	2021
Is there a therapeutic potential in combining bupropion and naltrexone in schizophrenia? Expert review of neurotherapeutics, 2022, Volume: 22, Issue:9 Topics: Bupropion; Dopamine; Humans; Naltrexone; Schizophrenia	2022
Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis. Pharmacogenomics, 2023, Volume: 24, Issue:5 Topics: Adult; Bupropion; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Naltrexone; Peptides; Pharmacogenetics; Protein Serine-Threonine Kinases; Venoms; Weight Loss	2023

Trials

25 trial(s) available for naltrexone and bupropion

Article	Year
Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology, 2005, Volume: 180, Issue:1 Topics: Adolescent; Adult; Aged; Bupropion; Choice Behavior; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Reinforcement, Psychology; Smoking Cessation; Tobacco Use Disorder	2005
Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. Journal of clinical psychopharmacology, 2005, Volume: 25, Issue:6 Topics: Adult; Bupropion; Cohort Studies; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Gambling; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Single-Blind Method; Socioeconomic Factors; Treatment Outcome	2005
Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring, Md.), 2009, Volume: 17, Issue:1 Topics: Adult; Animal Feed; Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Drug Therapy, Combination; Fasting; Female; Humans; Male; Mice; Mice, Obese; Naltrexone; Narcotic Antagonists; Obesity; Overweight; United States; Weight Loss	2009
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:12 Topics: Adolescent; Adult; Appetite; Bupropion; Cohort Studies; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Positron-Emission Tomography; Risk Factors; Weight Loss; Young Adult	2009
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addictive behaviors, 2010, Volume: 35, Issue:3 Topics: Adult; Bupropion; Cotinine; Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Weight Gain	2010
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:1 Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality Therapy; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Placebos; Treatment Outcome; Weight Loss	2011
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England), 2010, Aug-21, Volume: 376, Issue:9741 Topics: Adult; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Obesity; Overweight; Weight Loss	2010
[Six-month follow-up study of drug treatment for cannabis addiction: comparison study of four drugs]. Harefuah, 2011, Volume: 150, Issue:12 Topics: Adult; Bromazepam; Bupropion; Citalopram; Dopamine Uptake Inhibitors; Follow-Up Studies; GABA Modulators; Humans; Marijuana Abuse; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Dropouts; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires; Treatment Outcome; Young Adult	2011
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring, Md.), 2013, Volume: 21, Issue:5 Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Feeding Behavior; Female; Humans; Hypertension; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Obesity; Overweight; Quality of Life; Risk Factors; Weight Loss	2013
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes care, 2013, Volume: 36, Issue:12 Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight; Bupropion; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Retrospective Studies; Risk Factors; Treatment Outcome; Weight Loss; Young Adult	2013
Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. Clinical obesity, 2015, Volume: 5, Issue:5 Topics: Adult; Aged; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Quality of Life; Surveys and Questionnaires; Weight Loss; Young Adult	2015
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA, 2016, Mar-08, Volume: 315, Issue:10 Topics: Aged; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Bupropion; Cardiovascular Diseases; Confidence Intervals; Confidentiality; Double-Blind Method; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Humans; Internet; Male; Middle Aged; Myocardial Infarction; Naltrexone; Obesity; Overweight; Patient Selection; Placebo Effect; Risk Factors; Sample Size; United States; Weight Reduction Programs	2016
Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial. Clinical pharmacology and therapeutics, 2016, Volume: 100, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult	2016
The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. International journal of obesity (2005), 2016, Volume: 40, Issue:9 Topics: Adolescent; Adult; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Risk Factors; Treatment Outcome; Weight Loss; Young Adult	2016
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clinical obesity, 2016, Volume: 6, Issue:5 Topics: Adult; Anti-Obesity Agents; Body Mass Index; Bupropion; Combined Modality Therapy; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hypertension; Incidence; Lost to Follow-Up; Male; Naltrexone; Nausea; Obesity; Overweight; Patient Dropouts; Severity of Illness Index; United States; Weight Loss	2016
Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. Obesity (Silver Spring, Md.), 2017, Volume: 25, Issue:2 Topics: Adolescent; Adult; Body Weight; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Exercise; Feeding Behavior; Female; Humans; Life Style; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Obesity; Weight Loss; Young Adult	2017
A Preliminary, Open-Label Study of Naltrexone and Bupropion Combination Therapy for Treating Binge Drinking in Human Subjects. Alcohol and alcoholism (Oxford, Oxfordshire), 2020, Feb-07, Volume: 55, Issue:1 Topics: Adult; Binge Drinking; Bupropion; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Young Adult	2020
An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. Eating and weight disorders : EWD, 2021, Volume: 26, Issue:3 Topics: Binge-Eating Disorder; Bupropion; Case-Control Studies; Feeding Behavior; Humans; Naltrexone; Weight Loss	2021
Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. Clinical therapeutics, 2021, Volume: 43, Issue:1 Topics: Adult; Anti-Obesity Agents; Binge-Eating Disorder; Body Weight; Bupropion; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Pilot Projects; Treatment Outcome	2021
Bupropion and Naltrexone in Methamphetamine Use Disorder. The New England journal of medicine, 2021, 01-14, Volume: 384, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Amphetamine-Related Disorders; Bupropion; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Injections; Male; Medication Adherence; Methamphetamine; Middle Aged; Naltrexone; Narcotic Antagonists; Young Adult	2021
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. The American journal of psychiatry, 2022, 12-01, Volume: 179, Issue:12 Topics: Behavior Therapy; Binge-Eating Disorder; Bupropion; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Treatment Outcome; Weight Loss	2022
Naltrexone-bupropion combinations do not affect cocaine self-administration in humans. Pharmacology, biochemistry, and behavior, 2023, Volume: 224 Topics: Blood Pressure; Bupropion; Cocaine; Drug Combinations; Humans; Naltrexone	2023
Naltrexone plus bupropion reduces cigarette smoking in individuals with methamphetamine use disorder: A secondary analysis from the CTN ADAPT-2 trial. Journal of substance use and addiction treatment, 2023, Volume: 151 Topics: Bupropion; Cigarette Smoking; Humans; Methamphetamine; Naltrexone; Narcotic Antagonists; Prospective Studies	2023
A gender-based secondary analysis of the ADAPT-2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial. Addiction (Abingdon, England), 2023, Volume: 118, Issue:7 Topics: Adult; Bupropion; Central Nervous System Stimulants; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methamphetamine; Naltrexone; Pregnancy	2023
Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder. Drug and alcohol dependence, 2023, 09-01, Volume: 250 Topics: Bupropion; Double-Blind Method; Female; Homosexuality, Male; Humans; Male; Methamphetamine; Naltrexone; Prospective Studies; Sexual and Gender Minorities; Sexual Behavior	2023

Other Studies

73 other study(ies) available for naltrexone and bupropion

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24 Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Which metabolites circulate? Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5 Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations	2013
The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2004, Volume: 29, Issue:4 Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Benzamides; Brain; Brain-Derived Neurotrophic Factor; Bupropion; Desipramine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Tolerance; Gene Expression Regulation; Immobilization; In Situ Hybridization; Male; Midazolam; Naltrexone; Narcotic Antagonists; Piperazines; Rats; Rats, Sprague-Dawley; Receptor, trkB; Receptors, Opioid, delta; RNA, Messenger; Swimming; Time Factors; Up-Regulation	2004
Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice. Addictive behaviors, 2006, Volume: 31, Issue:11 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Bupropion; Dopamine Uptake Inhibitors; Female; Health Care Surveys; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Substance-Related Disorders; Taurine; Tobacco Use Disorder	2006
Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion. Journal of controlled release : official journal of the Controlled Release Society, 2006, Jun-28, Volume: 113, Issue:2 Topics: Administration, Cutaneous; Bupropion; Drug Carriers; Drug Delivery Systems; Drug Synergism; Humans; In Vitro Techniques; Naltrexone; Skin Absorption	2006
Synthesis and hydrolytic behavior of two novel tripartate codrugs of naltrexone and 6beta-naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agents. Bioorganic & medicinal chemistry, 2006, Oct-15, Volume: 14, Issue:20 Topics: Alcohol Deterrents; Bupropion; Drug Stability; Hydrolysis; Molecular Structure; Naltrexone; Smoking Cessation; Stereoisomerism; Structure-Activity Relationship; Time Factors	2006
Noradrenaline is necessary for the hedonic properties of addictive drugs. Vascular pharmacology, 2006, Volume: 45, Issue:4 Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Appetitive Behavior; Benzazepines; Biphenyl Compounds; Bupropion; Carbidopa; Cocaine; Dopamine beta-Hydroxylase; Dopamine Uptake Inhibitors; Droxidopa; Female; Genotype; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Morphine; Naltrexone; Narcotic Antagonists; Neurokinin-1 Receptor Antagonists; Norepinephrine; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D1; Reward; Substance-Related Disorders	2006
A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addictive behaviors, 2008, Volume: 33, Issue:1 Topics: Adult; Bupropion; Case-Control Studies; Combined Modality Therapy; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Smoking Cessation; Treatment Outcome; Weight Gain	2008
12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:6 Topics: Adolescent; Adult; Analysis of Variance; Bupropion; Delayed-Action Preparations; Drug Therapy; Fluvoxamine; Follow-Up Studies; Fructose; Gambling; Humans; Israel; Male; Middle Aged; Naltrexone; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Psychopharmacology; Recurrence; Reproducibility of Results; Surveys and Questionnaires; Time Factors; Topiramate	2007
In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2008, Apr-23, Volume: 33, Issue:4-5 Topics: Administration, Cutaneous; Alcohol-Related Disorders; Animals; Bupropion; Chromatography, High Pressure Liquid; Drug Delivery Systems; Female; Guinea Pigs; Male; Mass Spectrometry; Molecular Structure; Naltrexone; Prodrugs; Skin; Skin Absorption; Skin Irritancy Tests; Smoking Cessation	2008
Drug addiction: a critical problem calling for novel solutions. Clinical pharmacology and therapeutics, 2008, Volume: 83, Issue:4 Topics: Benzazepines; Buprenorphine; Bupropion; Chronic Disease; Financing, Government; Genetic Testing; Harm Reduction; Humans; Marijuana Smoking; Naltrexone; Narcotic Antagonists; Prevalence; Privacy; Quinoxalines; Receptors, Nicotinic; Recurrence; Risk-Taking; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Substance-Related Disorders; Varenicline	2008
[Preventing weight gain in smoking cessation: there is no miracle solution]. Revue medicale suisse, 2009, Aug-05, Volume: 5, Issue:212 Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Fluoxetine; Humans; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Risk; Selective Serotonin Reuptake Inhibitors; Smoking Cessation; Substance Withdrawal Syndrome; Weight Gain	2009
Is cardiometabolic risk improved by weight-loss drugs? Lancet (London, England), 2010, Aug-21, Volume: 376, Issue:9741 Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Naltrexone; Obesity; Risk Factors	2010
Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination? International journal of clinical practice, 2010, Volume: 64, Issue:11 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Body Mass Index; Bupropion; Delayed-Action Preparations; Drug Combinations; Drug Synergism; Female; Humans; Male; Middle Aged; Naltrexone; Numbers Needed To Treat; Obesity; Randomized Controlled Trials as Topic; Weight Loss; Young Adult	2010
New obesity pill: new hopes, old fears. Lancet (London, England), 2010, Dec-18, Volume: 376, Issue:9758 Topics: Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Approval; Drug Combinations; Exercise; Feeding Behavior; Humans; Life Style; Naltrexone; Narcotic Antagonists; Obesity; Seizures; Suicidal Ideation; United States; United States Food and Drug Administration	2010
Bupropion/naltrexone fixed-dose combination for the treatment of obesity. Drugs of today (Barcelona, Spain : 1998), 2011, Volume: 47, Issue:8 Topics: Animals; Bupropion; Clinical Trials as Topic; Drug Combinations; Humans; Naltrexone; Obesity	2011
Drug treatment of obesity. The Psychiatric clinics of North America, 2011, Volume: 34, Issue:4 Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupropion; Child; Drug Approval; Drug Combinations; Energy Intake; Exenatide; Female; Fructose; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lactones; Male; Metformin; Naltrexone; Narcotic Antagonists; Obesity; Orlistat; Patient Compliance; Peptides; Randomized Controlled Trials as Topic; Sympathomimetics; Topiramate; United States; United States Food and Drug Administration; Venoms	2011
What cost weight loss? Circulation, 2012, Mar-06, Volume: 125, Issue:9 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; Phentermine; Risk Assessment; Risk Factors; Topiramate; Weight Loss	2012
Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. European journal of pharmacology, 2013, Jan-05, Volume: 698, Issue:1-3 Topics: Animals; Appetite Depressants; Body Composition; Body Weight; Bupropion; Diet; Drug Interactions; Eating; Gene Expression Regulation; Gene Knockout Techniques; Islet Amyloid Polypeptide; Male; Mice; Naltrexone; Obesity; Rats; Time Factors	2013
Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash. Psychopharmacology, 2013, Volume: 228, Issue:2 Topics: Animals; Behavior, Animal; Bupropion; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eating; Male; Naltrexone; Narcotic Antagonists; Rats; Satiety Response; Video Recording	2013
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:9 Topics: Absorptiometry, Photon; Adiposity; Analysis of Variance; Body Composition; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Intra-Abdominal Fat; Male; Middle Aged; Naltrexone; Obesity; Tomography, X-Ray Computed; Treatment Outcome; Weight Loss	2013
Therapies for obesity and medication-associated weight gain. Journal of psychosocial nursing and mental health services, 2013, Volume: 51, Issue:5 Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined Modality Therapy; Diet, Reducing; Disease Models, Animal; Drug Combinations; Exercise; Fructose; Humans; Mood Disorders; Naltrexone; Obesity; Overweight; Phentermine; Psychotic Disorders; Randomized Controlled Trials as Topic	2013
Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. International journal of obesity (2005), 2014, Volume: 38, Issue:5 Topics: Adolescent; Adult; Appetite; Bupropion; Cues; Diet; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Ghrelin; Humans; Hypothalamus; Leptin; Magnetic Resonance Imaging; Meals; Naltrexone; Obesity; Peptide YY; Treatment Outcome; Weight Loss	2014
Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats. Behavioural pharmacology, 2014, Volume: 25, Issue:8 Topics: Animals; Benzazepines; Bupropion; Cholinergic Agents; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Male; Naltrexone; Narcotic Antagonists; Nicotine; Quinoxalines; Rats; Rats, Long-Evans; Reinforcement, Psychology; Varenicline	2014
Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids. Addiction biology, 2016, Volume: 21, Issue:2 Topics: Acamprosate; Analysis of Variance; Animals; Antidiuretic Hormone Receptor Antagonists; Bupropion; Dose-Response Relationship, Drug; Fructose; Indoles; Male; Motor Activity; Naltrexone; Nicotine; Nicotinic Agonists; Pyrrolidines; Rats, Wistar; Taurine; Tobacco Use Cessation Devices; Topiramate	2016
Contrave--a combination of bupropion and naltrexone for weight loss. The Medical letter on drugs and therapeutics, 2014, Nov-10, Volume: 56, Issue:1455 Topics: Anti-Obesity Agents; Bupropion; Drug Approval; Drug Combinations; Drug Interactions; Humans; Naltrexone; Obesity; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Weight Loss	2014
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. International journal of clinical practice, 2014, Volume: 68, Issue:12 Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2014
Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2014, Volume: 61, Issue:10 Topics: Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Europe; Fructose; Humans; Naltrexone; Obesity; Phentermine; Product Surveillance, Postmarketing; Topiramate; United States; United States Food and Drug Administration	2014
Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine. Pharmacology, biochemistry, and behavior, 2015, Volume: 129 Topics: Administration, Intranasal; Adult; Bupropion; Humans; Methamphetamine; Naltrexone; Narcotic Antagonists; Surveys and Questionnaires	2015
Approval of antiobesity drug is "major regression for patients' safety," says health watchdog. BMJ (Clinical research ed.), 2014, Dec-23, Volume: 349 Topics: Anti-Obesity Agents; Bupropion; Drug Approval; Drug Combinations; Europe; France; Humans; Naltrexone; Patient Safety; United States	2014
Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug design, development and therapy, 2015, Volume: 9 Topics: Anti-Obesity Agents; Bupropion; Humans; Naltrexone; Obesity	2015
Nonincretin drugs in later-stage development. The American journal of managed care, 2014, Volume: 20, Issue:1 Spec No. Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Drug Labeling; Drugs, Investigational; Fructose; Humans; Naltrexone; Obesity; Phentermine; United States; United States Food and Drug Administration	2014
[Mysimba, an American appetite suppressant and the logic of the single European market]. Revue medicale suisse, 2015, Apr-15, Volume: 11, Issue:470 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Naltrexone; Obesity; Overweight	2015
Review of pharmacotherapy options for the management of obesity. Journal of the American Association of Nurse Practitioners, 2016, Volume: 28, Issue:2 Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; United States	2016
Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss. Prescrire international, 2015, Volume: 24, Issue:164 Topics: Anti-Obesity Agents; Blood Pressure; Bupropion; Drug Combinations; Drug Interactions; Humans; Mental Disorders; Naltrexone; Randomized Controlled Trials as Topic; Weight Loss	2015
What a waste! Prescrire international, 2015, Volume: 24, Issue:164 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Naltrexone; Randomized Controlled Trials as Topic	2015
Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted. JAMA, 2016, Mar-08, Volume: 315, Issue:10 Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Female; Humans; Male; Naltrexone; Obesity	2016
Time-to-Event Analysis. JAMA, 2016, Mar-08, Volume: 315, Issue:10 Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Female; Humans; Male; Naltrexone; Obesity	2016
Company is blamed for early halt of trial into obesity treatment. BMJ (Clinical research ed.), 2016, Mar-08, Volume: 352 Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Female; Humans; Male; Naltrexone; Obesity	2016
A new era of addiction treatment amplifies the stigma of disease and treatment for individuals with obesity. International journal of obesity (2005), 2016, Volume: 40, Issue:9 Topics: Anti-Obesity Agents; Attitude of Health Personnel; Behavior, Addictive; Bupropion; Drug Therapy, Combination; Humans; Naltrexone; Obesity; Patient Education as Topic; Social Stigma; Stereotyping; United States	2016
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. The Journal of family practice, 2016, Volume: 65, Issue:7 Suppl Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Primary Health Care; Risk Factors; Treatment Outcome; Weight Loss	2016
Influence of Naltrexone/Bupropion Combination Treatment on Body Mass Index in Prader-Willi Syndrome Re: "Prader-Willi Syndrome, Management of Impulsivity, and Hyperphagia in an Adolescent" by Puri et al. Journal of child and adolescent psychopharmacology, 2016, Volume: 26, Issue:9 Topics: Adolescent; Body Mass Index; Bupropion; Humans; Hyperphagia; Impulsive Behavior; Naltrexone; Prader-Willi Syndrome	2016
Improving efficacy of the adjustable gastric band: studies of the use of adjuvant approaches in a rodent model. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 2017, Volume: 13, Issue:2 Topics: Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Blood Glucose; Body Composition; Body Fat Distribution; Body Temperature; Bupropion; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Eating; Energy Metabolism; Gastroplasty; Glucose Intolerance; Injections, Subcutaneous; Insulin Resistance; Laparoscopy; Male; Naltrexone; Obesity; Physical Conditioning, Animal; Rats, Sprague-Dawley; Thermogenesis; Thyroxine; Weight Loss	2017
Acute Generalized Erythrodermic Pustular Psoriasis Associated with Bupropion/Naltrexone (Contrave The Journal of emergency medicine, 2017, Volume: 52, Issue:4 Topics: Acute Kidney Injury; Biopsy; Bupropion; Cyclosporine; Dermatologic Agents; Diagnosis, Differential; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Middle Aged; Naltrexone; Psoriasis; Stevens-Johnson Syndrome	2017
Obesity Epidemic: Pharmaceutical Weight Loss. Rhode Island medical journal (2013), 2017, Mar-01, Volume: 100, Issue:2 Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Weight Loss	2017
Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample. International journal of obesity (2005), 2017, Volume: 41, Issue:8 Topics: Adult; Bupropion; Clinical Trials, Phase III as Topic; Craving; Dopamine Uptake Inhibitors; Feeding Behavior; Female; Food Preferences; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Psychometrics; Surveys and Questionnaires; Treatment Outcome; Weight Loss	2017
Perioperative Pain Management of a Patient Taking Naltrexone HCl/Bupropion HCl (Contrave): A Case Report. A & A case reports, 2017, Oct-15, Volume: 9, Issue:8 Topics: Bupropion; Diskectomy; Drug Combinations; Humans; Naltrexone; Narcotic Antagonists; Pain Management; Perioperative Care	2017
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study. Advances in therapy, 2017, Volume: 34, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Binge-Eating Disorder; Bupropion; Comorbidity; Depressive Disorder, Major; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Overweight	2017
Application of wavelet and Fuorier transforms as powerful alternatives for derivative spectrophotometry in analysis of binary mixtures: A comparative study. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2018, 02-15, Volume: 191 Topics: Bupropion; Chromatography, High Pressure Liquid; Fourier Analysis; Naltrexone; Spectrophotometry; Wavelet Analysis	2018
Co-Administration of Low-Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats. Alcoholism, clinical and experimental research, 2018, Volume: 42, Issue:3 Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Behavior, Animal; Bupropion; Central Nervous System Depressants; Dopamine Uptake Inhibitors; Ethanol; Male; Naltrexone; Rats; Self Administration	2018
Bupropion and naltrexone combination alters high fructose corn syrup self-administration and gene expression in rats. Neuropharmacology, 2018, Volume: 135 Topics: Animals; Anti-Obesity Agents; Brain; Bupropion; Drug Combinations; Feeding Behavior; Gene Expression Regulation; High Fructose Corn Syrup; Male; Motor Activity; Naltrexone; Random Allocation; Rats, Sprague-Dawley; Reward; RNA, Messenger; Self Administration	2018
Effect of combined naltrexone and bupropion therapy on the brain's functional connectivity. International journal of obesity (2005), 2018, Volume: 42, Issue:11 Topics: Adult; Appetite; Appetite Depressants; Brain Mapping; Bupropion; Cues; Drug Combinations; Eating; Fasting; Feeding Behavior; Female; Humans; Magnetic Resonance Imaging; Naltrexone; Neural Pathways; Parietal Lobe; Treatment Outcome; Young Adult	2018
Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK. Clinical obesity, 2018, Volume: 8, Issue:3 Topics: Anti-Obesity Agents; Bariatric Surgery; Body Weight Maintenance; Bupropion; Health Services; Humans; Life Style; Liraglutide; Naltrexone; Obesity; Primary Health Care; Specialization; State Medicine; United Kingdom; Weight Loss; Weight Reduction Programs	2018
Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. International journal of obesity (2005), 2019, Volume: 43, Issue:10 Topics: Anti-Obesity Agents; Bupropion; Double-Blind Method; Drug Combinations; Humans; Mood Disorders; Naltrexone; Obesity; Overweight; Prospective Studies; Randomized Controlled Trials as Topic	2019
Bupropion, Alone and in Combination with Naltrexone, Blunts Binge-Like Ethanol Drinking and Intake Following Chronic Intermittent Access to Ethanol in Male C57BL/6J Mice. Alcoholism, clinical and experimental research, 2019, Volume: 43, Issue:5 Topics: Alcohol Deterrents; Animals; Binge Drinking; Bupropion; Central Nervous System Depressants; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethanol; Male; Mice; Mice, Inbred C57BL; Naltrexone; Self Administration	2019
Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert opinion on drug safety, 2019, Volume: 18, Issue:7 Topics: Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Naltrexone; Obesity	2019
The Persistent Challenge of Developing Addiction Pharmacotherapies. Cold Spring Harbor perspectives in medicine, 2021, 11-01, Volume: 11, Issue:11 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bupropion; Central Nervous System Stimulants; Cocaine-Related Disorders; Drug Therapy; Humans; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Smoking Cessation Agents; Substance-Related Disorders; Varenicline	2021
Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study. Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:3 Topics: Bupropion; Genotype; Humans; Naltrexone; Pilot Projects; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Receptors, Dopamine D2; Weight Loss	2021
Extended-release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials. Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:3 Topics: Adult; Alanine Transaminase; Bupropion; Double-Blind Method; Female; Humans; Liver; Male; Naltrexone; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic	2021
[Pharmacotherapy for obesity]. Nederlands tijdschrift voor geneeskunde, 2021, 01-19, Volume: 165 Topics: Anti-Obesity Agents; Bariatric Surgery; Bupropion; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Humans; Hunger; Life Style; Liraglutide; Naltrexone; Obesity; Satiation; Treatment Outcome; Weight Loss	2021
Patch test-proven delayed-type hypersensitivity from naltrexone/bupropion possibly eliciting psoriasis. Contact dermatitis, 2021, Volume: 85, Issue:4 Topics: Acute Generalized Exanthematous Pustulosis; Anti-Obesity Agents; Bupropion; Female; Humans; Hypersensitivity, Delayed; Middle Aged; Naltrexone; Patch Tests; Psoriasis	2021
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. International journal of obesity (2005), 2021, Volume: 45, Issue:8 Topics: Aged; Anti-Obesity Agents; Body Weight; Bupropion; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Naltrexone; Obesity; Randomized Controlled Trials as Topic; Weight Loss	2021
Naltrexone/bupropion modifies weight, food intake, and Drd2 gene expression in rats. The Journal of endocrinology, 2022, 04-13, Volume: 253, Issue:3 Topics: Animals; Body Weight; Bupropion; Diet, High-Fat; Eating; Gene Expression; Naltrexone; Obesity; Rats; Rats, Wistar; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase	2022
Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats. Einstein (Sao Paulo, Brazil), 2022, Volume: 20 Topics: Animals; Bupropion; Humans; Male; Naltrexone; Obesity; Rats; Rats, Wistar; Subcutaneous Fat; Topiramate	2022
Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysis. The Journal of clinical psychiatry, 2022, 06-20, Volume: 83, Issue:4 Topics: Analgesics, Opioid; Buprenorphine; Bupropion; Central Nervous System Stimulants; Cross-Over Studies; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders	2022
Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. Obesity (Silver Spring, Md.), 2023, Volume: 31, Issue:5 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Health Care Costs; Health Services Accessibility; Liraglutide; Naltrexone; Orlistat; Phentermine; Topiramate	2023
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:9 Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Humans; Liraglutide; Naltrexone; Obesity; Overweight; Peptides; Proglucagon; Weight Loss	2023
Naltrexone-bupropion for weight loss. Canadian family physician Medecin de famille canadien, 2023, Volume: 69, Issue:9 Topics: Bupropion; Humans; Naltrexone; Weight Loss	2023
Canadian family physician Medecin de famille canadien, 2023, Volume: 69, Issue:9 Topics: Bupropion; Humans; Naltrexone; Weight Loss	2023